Navigation Links
Researchers issue state-of-the-state on genetic-based testing and treatment for breast cancer
Date:3/25/2014

(Lebanon, NH, 03/24/2014)- Dartmouth researchers at its Norris Cotton Cancer Center have compiled a review of the role that information gathered through genetic testing plays in the diagnosis and treatment of breast cancer. The paper entitled "Personalized Therapy for Breast Cancer" was accepted on March 17, 2014, for publication in Clinical Genetics. The paper discusses targeted therapies, new biomarkers, and the quality of commercially available testing methods.

Genomic testing is changing the way breast cancer is diagnosed and treated. By examining a woman's genes to look for specific mutations or biomarkers, treatment can be personalized to the tumor cell's biology and a woman's genetics.

"A personalized approach increases the precision and success of breast cancer treatment," said Gregory Tsongalis, PhD, director of Molecular Pathology at Norris Cotton Cancer Center and lead author of the paper. "Molecular profiling exposes a tumor's Achilles' heel. We can see what messages the tumor cells are receiving and sending. It is a biological intelligence gathering mission in an attempt to interrupt the disease.

According to Tsongalis large scale genetic testing of breast cancer is not yet part of routine clinical care as it is with lung and colon cancers, even though he and his team run a genetics laboratory for routine cancer care. Genetic testing according to Tsongalis is a powerful weapon in the diagnosis and treatment of breast cancer.

With results from the genetic testing of a tumor cell's biology, clinicians categorize breast cancer in ways that allow them to select the most effective treatments. Based on genetic biomarkers, there are three categories of breast cancer:

  • ER-positive breast cancer needs hormones, such as estrogen to grow. Estrogen fuels cancer cell growth, stops cancer cells from dying, and helps the cells lay down roots to maintain blood supply for tumors. ER-positive cancers are less aggressive and often treated with drugs that are selective estrogen receptor modulators (SERM), such as Tamoxifen, Raloxifene, Toremifene and aromatese inhibitors (AIs) such as Letrozole, Anastrozole and Exemestane. SERM drugs block estrogen from telling cancer cells to divide and grow; they have been shown successful in treating as well as preventing ER positive breast cancer. AIs block intake of estrogen in the system and reduce estrogen levels in serum, tissue, and tumor cells. AIs are commonly used in post-menopausal women.

  • HER2 positive breast cancer cells contain large amounts of protein that help them grow and multiply. Medications turn off the production of protein to stop tumor growth and kill cancer cells. HER2 treatments include Trastuzumab, Laptinib, Pertuzumab, and Trastuzumab Emtansine.

  • Triple negative (ER-negative/PR-negative/HER2-negative) breast cancer is the most aggressive type and has the poorest clinical outcome. There is no approved personalized therapy for triple negative, but research has identified six subtypes of tumors. This is the first step in identifying biomarkers that can lead to the development of personalized treatments.

"Genomic testing of breast cancer has expanded our understanding of the disease process and has proven more effective than traditional laboratory tests," said Tsongalis. "At NCCC all of our breast cancer patients are tested for abnormal copies of the HER2 gene using specially designed DNA probes."New biomarkers and the reclassification of cancers based on these biomarkers has led to the development of new, effective treatments that can be personalized to an individual breast cancer patient."


'/>"/>
Contact: Donna Dubuc
donna.M.Dubuc@Dartmouth.edu
603-653-3615
The Geisel School of Medicine at Dartmouth
Source:Eurekalert

Related medicine news :

1. Researchers identify impaired new learning in persons with Parkinsons disease
2. Researchers identify potential new therapeutic target for controlling high blood sugar
3. Ottawa researchers find new pathway connected to type 2 diabetes
4. Shoulder revision repair surgery not as successful 2 years later, say researchers
5. Researchers find significant increase in painkillers prescribed to US adults in the ER
6. Dartmouth researchers develop new approach to chronic lymphocytic leukemia treatment
7. Researchers destroy cancer with cryoablation & nanoparticle-encapsulated anticancer drug
8. NYU researchers find majority of Latinas are unaware of their risk of diabetes
9. UF researchers find drug therapy that could eventually reverse memory decline in seniors
10. Researchers identify carbohydrates in a coal mine for cancer detection
11. Researchers X-ray living cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... ... , ... Altec Products, Inc., a leader in enterprise document management ... Irvine, CA. The four-day training session, which begins today and continues through Thursday ... DocLink more efficiently and effectively. , Covering topics such as Smart Form Toolkit, ...
(Date:9/18/2017)... ... ... Allegheny Health Network’s (AHN) string of standout showings at the Pittsburgh Business ... more honors than any health care provider in the region at the annual event. ... Omni William Penn Hotel in downtown Pittsburgh included:, , George ...
(Date:9/18/2017)... York, NY (PRWEB) , ... September 18, 2017 , ... Prostate cancer is the second ... NFL game will be diagnosed with this disease, but the odds increase to 1 in ... history. These are stats that no one wants to see up on a scoreboard. , ...
(Date:9/18/2017)... Mirada, CA (PRWEB) , ... September 18, 2017 ... ... offering chiropractic care to patients in Southern California. Patients with chronic ... highly-skilled techniques and services provided by Healthpointe’s chiropractic department. , Each of Healthpointe’s ...
(Date:9/18/2017)... ... September 18, 2017 , ... Rock Jensen, ... for the new book compiled by the Association for the Healthcare Environment ... work of a carefully-assembled Staffing Task Force. “We’re incredibly proud of the ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017   PDI , a leader ... will host an educational session focused on the role ... (CLABSI) prevention at the 2017 Annual Scientific Meeting of ... take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s Prevantics® ...
(Date:9/5/2017)... KEYSTONE, Colo. , Sept. 5, 2017 ... their XR-29 DoseCheck solution. Scannerside DoseCheck is a third-party ... update existing CT scanners and allows compliance with current ... The Sapheneia-Scannerside proprietary XR 29 DoseCheck solution is specifically ... notifications and alerts of potential radiation doses over a ...
(Date:9/5/2017)... 2017  Just 18 months after its February 2016 ... announce the appointment of three new senior people to ... Dominic Jones-Phillips and James Wright bring ... Tammy Wynne joins as ... writers. She has over ten years, experience in global ...
Breaking Medicine Technology: